AMCP Nexus 2018

Cost-Effectiveness of Patiromer for Hyperkalemia in CKD Patients Using RAASIs

Orlando—Renin-angiotensin-aldosterone system inhibitors (RAASIs) are of benefit to patients with chronic kidney disease (CKD); however, providers may avoid or discontinue use of RAAIs due to concerns related to RAASI-induced hyperkalemia. Patiromer is a non-absorbed potassium-binding polymer for the treatment of hyperkalemia, including patients on RAASIs. Mark Bounthavong, PharmD, MPH, and colleagues recently conducted a study to assess the cost-effectiveness of ... Read More »

Real-World Utilization of Patiromer among Medicare Advantage Patients

Orlando—The real-world utilization of patiromer, a sodium-free, potassium-binding polymer, in the treatment of hyperkalemia was the subject of a study conducted recently by Robert Toto, MD, and colleagues. The study included patients with hyperkalemia who had Medicare Advantage insurance. Study results were reported during a poster session at AMCP NEXUS 2018 in a poster titled Real-World Utilization of Hyperkalemia Management ... Read More »